Insight

Stephen V Liu Shared ORCHARD Study Results on Osimertinib Plus Necitumumab in EGFR-Mutated NSCLC Published in JCO

Stephen V Liu/X

Jun 8, 2025, 16:34

Stephen V Liu Shared ORCHARD Study Results on Osimertinib Plus Necitumumab in EGFR-Mutated NSCLC Published in JCO

Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared a post on X:

“Results from Osimertinib + Necitumumab module of phase II ORCHARD study published in JCO.

Patients with EGFR-Mutated NSCLC with progression on osi and EGFR amplification or secondary EGFR mt received Osimertinib 80mg + Necitumumab D1/8 q21d. RR 11%, PFS 4m, OS 11.4m, 53% had G3+ AE.”

Title: ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib

Journal: JCO

Authors: Jonathan W. Riess, Adrianus J. de Langen, Santiago Ponce, Sarah B. Goldberg, Zofia Piotrowska, Jonathan W. Goldman, Xiuning Le, Byoung Chul Cho, Yasuto Yoneshima, Helen Ambrose, Riccardo Cavazzina, Kwan Ho Tang, James Lau, Helena A. Yu

Read the full article.

ORCHARD

Adrianus J de Langen Byoung Chul Cho cancer EGFR-mutated NSCLC Georgetown University Helen Ambrose Helena A. Yu James Lau Jonathan W. Goldman Jonathan W. Riess Kwan Ho Tang Necitumumab OncoDaily Oncology ORCHARD osimertinib Riccardo Cavazzina Santiago Ponce Sarah B. Goldberg Stephen V Liu Xiuning Le Yasuto Yoneshima Zofia Piotrowska

ASCO 2026 Presidential Theme: Dr. Eric Small’s Vision to Translate Science Into Global Cancer Impact

MiNK Therapeutics Stock Surges on Breakthrough Testicular Cancer Remission and iNKT Cell Therapy Progress

Tabelecleucel (Ebvallo) FDA Update: Approval Delayed Despite Positive Phase 3 Data

New Paper Alert: Breakthrough iNKT Cell Therapy Achieves Complete Remission in Metastatic Germ Cell Tumor

"God Invented This" - Pat Soon-Shiong on Cancer Discovery